HM15912 / Hanmi 
Welcome,         Profile    Billing    Logout  

3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
HM15912 / Hanmi
2021-000176-11: Study of HM15912 in subjects with Short Bowel Syndrome-associated Intestinal Failure

Ongoing
2
18
Europe
HM15912 (LAPS GLP-2 analog), HM15912 (LAPS GLP-2 analog), Solution for injection in pre-filled syringe
Hanmi Pharm. Co., Ltd., Hanmi Pharmaceutical Co., Ltd., Hanmi Pharm. Co., Ltd., Hanmi Pharmaceutical Co., Ltd.
Short Bowel Syndrome-associated Intestinal Failure (SBS-IF), Short bowel length. With intestinal failure, the length and function of the small intestine falls below the minimum necessary for the absorption of nutrients and water to maintain good health., Diseases [C] - Digestive System Diseases [C06]
 
 
NCT04775706 / 2021-000176-11: Phase 2 Study to Assess the Safety, PK, and PD in SBS-IF Subjects

Recruiting
2
18
Europe, US, RoW
HM15912 Active, Placebo
Hanmi Pharmaceutical Company Limited, Hanmi Pharm. Co., Ltd., Hanmi Pharmaceutical Co., Ltd.
Short Bowel Syndrome
12/25
12/25
NCT05711381: Phase 1 PK Study to Assess Safety, PK, Tolerability of HM15912 in Subjects With Renal Impairment and Normal Renal Function

Completed
1
16
US
HM15912
Hanmi Pharmaceutical Company Limited
Renal Impairment
08/23
08/23

Download Options